Immunovant Inc at Stifel Healthcare Conference (Virtual) Transcript
Good morning and welcome to the -- or good afternoon, I should say, and welcome to the 2021 Stifel healthcare conference. My name is Neil Carnahan. I am a research associate here at Stifel. This afternoon, I have the pleasure of introducing Dr. Pete Salzmann, CEO of Immunovant, the clinical-stage company focused on developing autoimmune therapeutics with a lead product candidate, IMVT-1401, a novel fully human anti-FcRn monoclonal antibody being developed in IgG antibody-mediated autoimmune diseases.
We have a question box at the bottom of your screen if you want to send there any questions. You can also reach me over email, neil.carnahan -- my name is in the bottom left of my screen -- @stifel.com.
With that, Dr. Salzmann, I'll let you to take it away.
Thanks, Neil. I appreciate the opportunity to share some information in today's conference. I'm going to begin today's presentation with a brief overview of the anti-FcRn market and then
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
